On April 2, 2026, Regenerex Pharma, Inc. filed an 8-K report detailing significant changes in its executive leadership. The company's Board of Directors has placed Chief Financial Officer Kenneth Perry on administrative leave with pay, effective immediately. This decision follows a review that raised concerns regarding compliance with Board directives, financial oversight, corporate governance, and the company's financial reporting processes and internal controls. While Mr. Perry will remain an employee during this period, his responsibilities have been reassigned to an interim CFO appointed by the Board. The interim CFO, Don E. Ray, will serve for an initial term of 90 days with an annual salary of $150,000. Mr. Ray brings a wealth of experience, having previously served as CFO for various organizations and as a consultant for public companies. The Board emphasized that the review of Mr. Perry's conduct is ongoing, and no final determinations have been made regarding the issues raised. This leadership change is expected to impact the company's governance and operational execution, potentially affecting investor confidence and stock performance in the near term.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.